

Alopecia Treatment Pipeline Review H1 2016

Global Alopecia Drugs and Companies Pipeline Review H1 2016

PUNE, INDIA, August 30, 2016 /EINPresswire.com/ -- Summary 'Alopecia - Pipeline Review, H2 2016', provides an overview of the Alopecia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects.

Complete report details @ https://www.wiseguyreports.com/reports/619287alopecia-pipeline-review-h2-2016



Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <u>https://www.wiseguyreports.com/sample-request/619287-alopecia-pipeline-review-h2-2016</u>

Scope

- The report provides a snapshot of the global therapeutic landscape of Alopecia

- The report reviews pipeline therapeutics for Alopecia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Alopecia therapeutics and enlists all their major and minor projects

- The report assesses Alopecia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Alopecia Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Alopecia

- Identify potential new clients or partners in the target demographic

Key points in table of content

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <u>https://www.wiseguyreports.com/enquiry/619287-alopecia-pipeline-review-h2-2016</u>

Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Alopecia Overview 8 **Therapeutics Development 9** Pipeline Products for Alopecia - Overview 9 Pipeline Products for Alopecia - Comparative Analysis 10 Alopecia - Therapeutics under Development by Companies 11 Alopecia - Therapeutics under Investigation by Universities/Institutes 13 Alopecia - Pipeline Products Glance 14 Late Stage Products 14 **Clinical Stage Products 15** Early Stage Products 16 Alopecia - Products under Development by Companies 17 Alopecia - Products under Investigation by Universities/Institutes 20 Alopecia - Companies Involved in Therapeutics Development 21 Ache Laboratorios Farmaceuticos S/A 21 Aclaris Therapeutics, Inc. 22 Allergan Plc 23

Almirall, S.A. 24 AndroScience Corporation 25 Berg LLC 26 BiologicsMD, Inc. 27 Bristol-Myers Squibb Company 28 Concert Pharmaceuticals, Inc. 29 **Diffusion Pharmaceuticals Inc. 30** Follicum AB 31 Handok Inc. 32 Histogen, Inc. 33 Hyundai Pharmaceutical Co., Ltd. 34 Incyte Corporation 35 Kuhnil Pharmaceutical Co., Ltd. 36 Lee's Pharmaceutical Holdings Limited 37 LEO Pharma A/S 38 NovaLead Pharma Pvt. Ltd. 39 Novartis AG 40 Panacea Biotec Limited 41 Quark Pharmaceuticals, Inc. 42 RepliCel Life Sciences, Inc. 43 RXi Pharmaceuticals Corporation 44 Sucampo Pharmaceuticals, Inc. 45 SWITCH Biotech LLC 46 Taisho Pharmaceutical Holdings Co., Ltd. 47 TetraLogic Pharmaceuticals 48 Tigo GmbH 49 Valeant Pharmaceuticals International, Inc. 50 Vida Therapeutics Inc. 51 Alopecia - Therapeutics Assessment 52 Assessment by Monotherapy Products 52 Assessment by Target 53 Assessment by Mechanism of Action 56 Assessment by Route of Administration 59 Assessment by Molecule Type 61 **Drug Profiles 63** abatacept - Drug Profile 63 Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and **Oncology - Drug Profile 68** Antisense Oligonucleotide to Antagonize Androgen Receptor for Alopecia - Drug Profile 69 ASCJ-9 - Drug Profile 70 ATI-50001 - Drug Profile 72 ATI-50002 - Drug Profile 73 bimatoprost - Drug Profile 74 BMD-1141 - Drug Profile 76 BMD-1341 - Drug Profile 77 BMD-2341 - Drug Profile 78 BQ-A - Drug Profile 79 BRM-421 - Drug Profile 80 calcitriol - Drug Profile 81 CB-0301 - Drug Profile 82 CTP-543 - Drug Profile 84 DHL-HisZnNa - Drug Profile 85

diphencyprone - Drug Profile 86 finasteride - Drug Profile 88 finasteride - Drug Profile 89 FOL-005 - Drug Profile 90 FS-2 - Drug Profile 93 Hair Stimulating Complex - Drug Profile 94 HL-5945 - Drug Profile 96 HTB-005 - Drug Profile 97 interferon beta-1b - Drug Profile 98 KI-1104 - Drug Profile 99 KI-1105 - Drug Profile 100 LEO-124249 - Drug Profile 101 minoxidil - Drug Profile 102

Buy this report @ <u>https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619287</u>

Norah Trent wiseguyreports +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2016 IPD Group, Inc. All Right Reserved.